Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review

Shaheen E Lakhan*, Karen F Vieira

Abstract

Background: Over the past several decades, complementary and alternative medications have increasingly become a part of everyday treatment. With the rising cost of prescription medications and their production of unwanted side effects, patients are exploring herbal and other natural remedies for the management and treatment of psychological conditions. Psychological disorders are one of the most frequent conditions seen by clinicians, and often require a long-term regimen of prescription medications. Approximately 6.8 million Americans suffer from generalized anxiety disorder. Many also suffer from the spectrum of behavioural and physical side effects that often accompany its treatment. It is not surprising that there is universal interest in finding effective natural anxiolytic (anti-anxiety) treatments with a lower risk of adverse effects or withdrawal.

Methods: An electronic and manual search was performed through MEDLINE/PubMed and EBSCO. Articles were not discriminated by date of publication. Available clinical studies published in English that used human participants and examined the anxiolytic potential of dietary and herbal supplements were included. Data were extracted and compiled into tables that included the study design, sample population, intervention, control, length of treatment, outcomes, direction of evidence, and reported adverse events.

Results: A total of 24 studies that investigated five different CAM monotherapies and eight different combination treatments and involved 2619 participants met the inclusion criteria and were analyzed. There were 21 randomized controlled trials and three open-label, uncontrolled observational studies. Most studies involved patients who had been diagnosed with either an anxiety disorder or depression (n = 1786). However, eight studies used healthy volunteers (n = 877) who had normal levels of anxiety, were undergoing surgery, tested at the upper limit of the normal range of a trait anxiety scale, had adverse premenstrual symptoms or were peri-menopausal, reported anxiety and insomnia, or had one month or more of elevated generalized anxiety. Heterogeneity and the small number of studies for each supplement or combination therapy prevented a formal meta-analysis. Of the randomized controlled trials reviewed, 71% (15 out of 21) showed a positive direction of evidence. Any reported side effects were mild to moderate.

Conclusions: Based on the available evidence, it appears that nutritional and herbal supplementation is an effective method for treating anxiety and anxiety-related conditions without the risk of serious side effects. There is the possibility that any positive effects seen could be due to a placebo effect, which may have a significant psychological impact on participants with mental disorders. However, based on this systematic review, strong evidence exists for the use of herbal supplements containing extracts of passionflower or kava and combinations of L-lysine and L-arginine as treatments for anxiety symptoms and disorders. Magnesium-containing supplements and other herbal combinations may hold promise, but more research is needed before these products can be recommended to patients. St. John’s wort monotherapy has insufficient evidence for use as an effective anxiolytic treatment.
Background
Mental disorders plague millions of people around the world. Depression and anxiety are two of the most common mental disorders, affecting nearly 55 million people in the United States alone [1]. The complexities of the central nervous system make diagnoses, treatment, and amelioration of these debilitating illnesses exceptionally difficult. Advancement in these areas would be invaluable in the effort to reduce the global impact of anxiety-based conditions. The universality of herbal remedies in many cultures makes them an appropriate treatment to explore.

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), anxiety is characterized by a feeling of persistent worry that hinders an individual’s ability to relax [2]. This can range from the transient anxiety levels a person feels before surgery or a menstrual cycle to the pervasive feeling of nervousness that characterizes an anxiety disorder (e.g., generalized anxiety disorder, obsessive-compulsive disorder, panic disorder and social phobia). The impact of the anxiety is not limited to consistent stress, which is associated with higher risk of cardiovascular and cerebrovascular disease [3]. Anxiety has also debilitating physical manifestations such as headaches, uncontrolled trembling and sweating, muscle tension and aches, among others.

To date, the biological explanations for many types of anxiety disorders remain inadequate. Postulations have implicated a dysregulation of specific neurotransmitters such as serotonin, dopamine and gamma-aminobutyric acid (GABA) as potential causes for both depression and anxiety disorders [4-6]. These hypotheses are based on the results of pharmacological treatments, but there are no definitive clinical trials that demonstrate the dysregulation of these neurotransmitters as causative factors of anxiety, potentially explaining why the treatment of anxiety with antidepressants is often ineffective. Thus far, cognitive behavioral therapy (CBT) has proven to be the most effective, long-term treatment for anxiety-related disorders [7].

With the lifetime prevalence of anxiety disorders reaching 16.6% worldwide [8], great strides have been made with ongoing research into its causes and treatments. In addition to antidepressants, serotonin-specific reuptake inhibitors (SSRIs) and benzodiazepines have also been prescribed to patients suffering from GAD [9,10]. However, while often effective, both of these classes of drugs come with many unwanted side effects such as suicidal ideation, decreased alertness, sexual dysfunction and dependency [11-16]. Additionally, the costs of these medications pose problems to patients who must take them on a daily, long-term basis.

As a result, there has been increased interest in the use of complementary and alternative medicines (CAM) as a natural method for treating numerous types of anxiety. Herbs such as passionflower, kava, St. John’s wort and valerian root, as well as the amino acid lysine and the cation magnesium, have been used for centuries in folk and traditional medicine to calm the mind and positively enhance mood. However, the efficacy and safety of utilizing CAMs to treat anxiety, both as a symptom and as a disorder, has only just begun to be rigorously tested in clinical trials within the last 10 to 15 years [17-19].

A number of reviews of the clinical effectiveness of herbal and nutrient treatments for depression, anxiety disorders, and sleep disturbance have been published over the past decade [19-25]. These have reviewed data associated with a number of treatments, including St. John’s Wort, S-adenosyl-methionine (SAM-e), B vitamins, inositol, choline, kava, omega-3 fatty acids/fish extracts, valerian, lavender, melatonin, passionflower, skullcap, hops, lemon balm, black cohosh, ginkgo biloba, extracts of Magnolia and Phellondendron bark, gamma-aminobutyric acid (GABA), theanine, tryptophan and 5-hydroxytryptophan (5-HTP). However, none of these studies has been conducted in a systematic way.

The objective of this paper is to systematically review and summarize the available literature on herbal remedies and dietary supplements for treating anxiety and related symptoms in order to aid mental health practitioners in advising their patients and provide insight for future research in this field.

Methods
Search strategy
MEDLINE/PubMed and EBSCO databases were searched without regard for date of publication, using the search terms “alternative therapies,” “herbal supplement” and individual herb and supplement names from popular sources, each crossed with the term “anxiety.” In addition, key publications were hand-searched for references. [See Additional file 1 for a Quality of Reporting of Meta-analyses (QUOROM) statement checklist.]

Selection criteria
The search was restricted to herbs and supplements that acted as anxiolytic agents and whose effects were measured either through quantitative rating scales or self-reports. Studies also had to be published in English, conducted with human subjects, have a sample size greater than 10, use a whole extract of the plant (if applicable) and detail data clearly. Case studies, review articles, meta-analyses, safety trials and studies that attempted to link vitamin and mineral deficiencies to the presence or absence of anxiety symptoms were excluded, as were trials in animals. Studies of anxiety...
parameters in healthy volunteers were also examined to provide supporting evidence.

Data abstraction and synthesis of results

Study results were abstracted into data tables (Tables 1, 2, 3, 4, 5, 6). Because of the heterogeneous nature of the patients, preparations and outcome measures, data pooling was not possible. Therefore, the data was summarized qualitatively. The most common outcome measures encountered in these trials included: Hamilton Anxiety Scale (HAMA), State Trait Anxiety Inventory (STAI), Erlanger Anxiety, Tension and Aggression Scale (EAAS), Bf-S self-rating scale of well-being, Anxiety Sensitivity Index (ASI), and Clinical Global Impressions (CGI) scale. Some studies used measurements of anxiety biomarkers such as adrenocorticotropic hormone, cortisol, adrenaline, noradrenaline and chromogranin-A levels; skin conductance; heart rate; and blood pressure. A significant positive change in at least one of the primary outcome measures was required to categorize the trial as positive.

### Table 1 Participant characteristics

|                | Passionflower | Kava | St. John’s wort | Lysine | Magnesium | All studies |
|----------------|---------------|------|----------------|--------|-----------|-------------|
| Patients (n)   | 278           | 1054 | 762            | 137    | 388       | 2619        |

| Gender         |               |      |                |        |           |             |
|----------------|---------------|------|----------------|--------|-----------|-------------|
| Male           | 46 (17%)      | 227  | 246 (32%)      | 83 (61%) | 130 (34%) | 732 (28%)   |
| Female         | 50 (18%)      | 759  | 516 (68%)      | 54 (39%) | 258 (66%) | 1637 (63%)  |
| Not Reported   | 182 (65%)     | 68   | -              | -       | -         | 250 (9%)    |

| Age range (years) | 19-47         | 18-75 | 18-65 | 20-59 | 18-82 | 18-82 |

| Race/Ethnicity      |               |       |       |       |       |       |
|---------------------|---------------|-------|-------|-------|-------|-------|
| Asian               | -             | 2 (< 1%) | -     | 108 (79%) | - | 110 (4%) |
| Caucasian           | -             | 401 (38%) | 83 (11%) | 29 (21%) | - | 513 (20%) |
| African American    | -             | 14 (1%)  | -     | -     | 14 (1%) | 513 (20%) |
| Hispanic            | -             | 7 (< 1%) | -     | -     | 7 (< 1%) | 513 (20%) |
| Native American     | -             | 7 (< 1%) | -     | -     | 7 (< 1%) | 513 (20%) |
| Not Reported        | 278 (100%)    | 623 (59%) | 679 (89%) | 316 (100%) | 1896 (72%) | 513 (20%) |

### Table 2 Trials testing passionflower

| Reference          | Study Design         | Sample Population | Intervention                  | Control          | Length of Treatment | Outcomes                  | Direction of Evidence | Reported Adverse Events |
|--------------------|----------------------|-------------------|-------------------------------|------------------|--------------------|--------------------------|-----------------------|------------------------|
| Bourin (1997) [34] | Randomized; Double-blind; Parallel Group | 182 outpatients with adjustment disorder with anxious mood | Euphytose[^1^]; 2 tablets, 3 times a day | Placebo tablets | 28 days | Significant reduction in HAMA scores (from D7 to D28) in favour of Euphytose treatment | + | No serious AEs. Dry mouth Headache Constipation Drowsiness |
| Akhondzadeh (2001) [32] | Randomized; Double-blind; Parallel group | 36 outpatients with DSM-IV for GAD for at least 6 months | 45 drops/day of Passiflora extract plus placebo tablet | Oxazepam 30 mg/day plus placebo drops | 4 weeks | Decrease in HAMA for both treatments[^2^]; overall no significant difference in efficacy between treatments | + | Higher impairment of job performance in oxazepam group; overall no significant difference in total side effects[^3^] |
| Movafegh (2008) [33] | Randomized; Double-blind; Parallel Group | 60 patients undergoing inguinal herniorrhaphy | Oral Passiflora incarnata (500 mg, Passipy™ IranDarouk) | Placebo | Given as premedication 90 minutes before surgery | NRS anxiety scores were significantly lower in the passiflora group | + | Not reported |

AEs: Adverse events; HAMA: Hamilton Anxiety Scale; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; GAD: generalized anxiety disorder; NRS: numerical rating scale.

[^1^]: Combination of *Crataegus oxyacantha* (10 mg), *Ballota foetida* (10 mg), *Passiflora incarnata* (40 mg), *Valeriana officinalis* (50 mg), *Cola nitida* (15 mg) and *Paullinia cupana* (15 mg).
[^2^]: D4 oxazepam; D7 passiflora.
[^3^]: Passiflora, mild/moderate: Dizziness, Drowsiness, Confusion, Ataxia, Allergic reaction, Impairment of job performance.
| Reference          | Study Design               | Sample Population                                      | Intervention                        | Control                 | Length of Treatment | Outcomes                                                                 | Direction of Evidence | Reported Adverse Events |
|--------------------|----------------------------|--------------------------------------------------------|-------------------------------------|-------------------------|---------------------|--------------------------------------------------------------------------|------------------------|------------------------|
| Volz (1997) [42]   | Randomized; Double-blind; Parallel Group | 101 outpatients with anxiety of non-psychotic origin¹ | Kava-kava extract WS 1490 (90-110 mg dry extract = 70 mg kl per capsule) | Placebo                 | 24 weeks            | Significant reduction in anxiety (HAMA, CGI, SCL-90-R, AMS) in favour of kava-kava treatment. | +                      | Excellent tolerability, similar to placebo; no clinically relevant changes in laboratory results. Stomach upset. |
| Scherer (1998)* [48] | Open-label; Uncontrolled Observational study | 52 outpatients with nonpsychotic anxiety | Kava preparation (no dose reported in abstract) | N/A                     | Not reported in abstract | 42 patients (80.8%) rated kava treatment as "very good" or "good". | +                      | Rare                   |
| Malsch (2001) [45] | Randomized; Double-blind; Parallel group | 40 adult outpatients with non-psychotic nervous anxiety, tension and restlessness, impairing work performance, normal social activities and relationships² | Pre-treatment with benzodiazepines (tapered off over two weeks) followed by capsules of 50 mg/day of dry extract standardized to 35 mg kava lactone for three weeks | Pre-treatment with benzodiazepines (tapered off over two weeks) followed by placebo for three weeks | 5 weeks               | Significant reduction in anxiety (HAMA, BF-S, EAAS, CGI) in kava-treated group. | +                      | No serious adverse events |
| Watkins (2001) [44] | Randomized; Double-blind; Parallel Group | 13 patients with GAD | Kava 280 mg/day (standardized to 30% kavalactones) | Placebo                 | 4 weeks              | Significant improvement in baroreflex control of heart rate in kava-treated group, respiratory sinus arrhythmia did not respond to kava treatment. | +                      | Not reported           |
| Connor (2002) [52] | Randomized; Double-blind; Parallel Group | 38 adults with DSM-IV GAD³ | Kava (standardized to 70 mg kavalactones [kl]). Treatment initiated at 149 mg kl/day and increased to 280 mg kl/day for the next 3 weeks. | Placebo                 | 4 weeks              | No significant difference to placebo⁴ | -                      | Well tolerated. No evidence of withdrawal or sexual side effects. |
| Boemer (2003) [43] | Randomized; Double-blind; Parallel Group | 129 outpatients diagnosed with GAD (GAD; ICD-10: F41.1) | 400 mg/day Kava extract LI 150 (standardized to 30% kavapyrones, extraction solvent 96% ethanol in water, drug-extract ratio 13-20:1) | (1) 10 mg/day Buspirone or (2) 100 mg/day Opipranol | 8 weeks              | Kava was shown to be as effective as reference treatments; 75% of patients responded (50% reduction of HAMA score). | +                      | 1 treatment-related adverse event. No systematic difference between treatments. No liver toxicity reported⁷. |
| Cagnacci (2003) [46] | Randomized; Open; Parallel Groups (3) | 80 peri-menopausal women | Calcium (1 g/day) plus: (1) Kava-Kava,100 mg/day (55% of kavain; Natural Bradel, Milano, Italy) (2) Kava-Kava, 200 mg/day | Calcium (1 g/day) | 3 months | Significant reduction in STAI scores in favour of combination treatment. | +                      | Mild/moderate: Nausea Gastric pain. No liver toxicity. |

¹ The sample size is for those with anxiety of non-psychotic origin.
² The sample size is for those with non-psychotic nervous anxiety, tension and restlessness.
³ The sample size is for those with non-psychotic GAD.
⁴ The sample size is for those with non-psychotic GAD.
⁵ The sample size is for those with non-psychotic GAD.
⁶ The sample size is for those with non-psychotic GAD.
⁷ The sample size is for those with non-psychotic GAD.
Table 3: Trials testing kava (Continued)

| Study          | Design       | Participants                                      | Intervention                                                                 | Comparator        | Duration | Results                                                                 | Adverse Events |
|----------------|--------------|---------------------------------------------------|-------------------------------------------------------------------------------|-------------------|----------|--------------------------------------------------------------------------|----------------|-----------------|----------------|
| Gastpar (2003) | Randomized;  | 141 adult outpatients diagnosed with neurotic    | 150 mg/day kava special extract WS 1490 (standardized to 35 mg kl)           | Placebo           | 4 weeks  | Pronounced decrease in ASI score for the kava group; however not        | Increased       |
|                | Double-blind; Parallel Group | anxiety                                      |                                                                               |                   |          | statistically significant overall; however an exploratory analysis of     | tiredness.      |
|                |              |                                                   |                                                                               |                   |          | variance across the differences between treatment end and baseline,     | No liver toxicity |
|                |              |                                                   |                                                                               |                   |          | with center as a second factor, showed superiority of kava over placebo. |                 |
| Jacobs (2005)  | Randomized;  | 391 healthy volunteers with anxiety7 and insomnia| (1) 100 mg kl/day kava (30% total kavalactones in extract) with valerian      | Double placebo    | 28 days  | Greater reductions in placebo group, but not statistically significant   | -               |
|                | Double-blind; Parallel Group |                                                   | placebo (2) 6.4 mg/day valerian (1% valerenic acid in extract) with kava   |                   |          | (STAI-State substest).                                                   | Similar         |
|                |              |                                                   | placebo                                                                |                   |          |                                                                          | frequency        |
|                |              |                                                   |                                                                               |                   |          |                                                                          | between          |
|                |              |                                                   |                                                                               |                   |          |                                                                          | treatments and   |
|                |              |                                                   |                                                                               |                   |          |                                                                          | placebo.         |
|                |              |                                                   |                                                                               |                   |          |                                                                          | No reports of    |
|                |              |                                                   |                                                                               |                   |          |                                                                          | liver toxicity   |
| Sarris (2009)  | Randomized;  | 41 adult participants with 1 month or more of    | Kava tablets (250 mg/day kavalactones)                                       | Placebo           | 3 weeks  | Highly significant reduction in anxiety (HAMA, BAI, MADRS) in kava-       | -               |
|                | Double-blind; Crossover | elevated generalized anxiety                   |                                                                               |                   |          | treated group.                                                           | No serious       |
|                |              |                                                   |                                                                               |                   |          |                                                                          | adverse events.  |
|                |              |                                                   |                                                                               |                   |          |                                                                          | Mild dizziness,  |
|                |              |                                                   |                                                                               |                   |          |                                                                          | nausea.          |
|                |              |                                                   |                                                                               |                   |          |                                                                          | No liver         |
|                |              |                                                   |                                                                               |                   |          | toxicity.                                                                | toxicity.        |
| Sarris (2009)  | Randomized;  | 28 adults with MDD and co-occurring anxiety       | Hypericum perforatum8 (1 × 1.8 g tablet, three times/day); Kava rhizome    | Placebo           | 4 weeks  | Combination treatment had no significant effects on anxiety (BDI-II)     | -               |
|                | Double-blind; Crossover |                                                   | aqueous extract9 (1 × 2.66 g tablet, 3 times/day)                           |                   |          |                                                                          | No serious       |
|                |              |                                                   |                                                                               |                   |          |                                                                          | adverse events.  |
|                |              |                                                   |                                                                               |                   |          |                                                                          | Mild gastrointestinal upset. |
|                |              |                                                   |                                                                               |                   |          |                                                                          | No liver toxicity |

HAMA: Hamilton Anxiety Scale; CGI: Clinical Global Impressions; SCL-90-R-ANX: Self-Report Symptom Inventory-90 Items revised, subscore somatic anxiety; AMS: Adjective Mood Scale; kl: kavalactones (kl); Bf-s: Befindlichkeitsskala [subjective well-being score]; EAAS: Erlanger Anxiety, Tension and Aggression Scale; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; GAD: generalized anxiety disorder; BAI: Beck Anxiety Inventory; BDI-II: Beck Depression Inventory-II; NADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; SARA: Self-Assessment of Resilience and Anxiety; HADS: Hospital Anxiety and Depression Scale.

* No full text available.

1. DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder and adjustment disorder with anxiety.
2. Diagnosis of agoraphobia (300.22), simple (300.29) or social phobia (300.23), generalized anxiety disorders (300.02) or adaptation disturbances (309.24) according to DSM-III-R.
3. According to the Results section, "Thirty-eight subjects were randomized, including 31 female (82%) and 32 Caucasian participants (97%)...Three subjects withdrew their consent following the baseline visit...and did not return for further assessment, leaving 35 subjects in the evaluable sample;" however, the Abstract states: "Thirty-seven adults with DSM-IV GAD were randomly assigned to...treatment."
4. Post-hoc analyses: kava was superior in low anxiety (SARA) and placebo was superior in high anxiety (HADS; SARA)
5. Slight increases in transaminase levels to above the upper limit of normal were reported in all three groups.
6. DSM-III-R diagnoses 300.02, 300.22, 300.23, 300.29, or 309.24.
7. Scores of at least 0.5 standard deviations above the mean on STAI-State.
8. Standardized to 990 μg of hypericin, and 1500 μg of flavone glycosides.
9. Standardized to 50 mg of kavalactones.
| Reference   | Study Design          | Sample Population                                                                 | Intervention                                      | Control | Length of Treatment | Outcomes                                                                 | Direction of Evidence | Reported Adverse Events |
|------------|-----------------------|-----------------------------------------------------------------------------------|--------------------------------------------------|---------|---------------------|----------------------------------------------------------------------------|------------------------|-------------------------|
| Taylor     | Open-label; Uncontrolled; Observational | 13 subjects with a primary DSM-IV diagnosis of OCD of at least 12 month duration | Fixed dose of 900 mg/day of 0.3% hypericin (a psychoactive compound in Hypericum) | N/A     | 12 weeks            | Significant improvement in Y-BOCS scores in SJW group (comparable to those seen in clinical trials with SSRIs). | +                      | Diarrhea Restless sleep |
| Volz       | Randomized; Double-blind; Parallel Group | 149 outpatients diagnosed with somatization Disorder, undifferentiated somatoform Disorder, or somatoform autonomic Dysfunctions | Hypericum extract LI 160 (600 mg/day) | Placebo | 6 weeks            | Significant reduction in anxiety (HAMA-SOM, CGI, HAMA-PSY, HDS, SCL-90-R, SCL-90-R-ANX) in favour of SJW treatment. | +                      | Verywell tolerated. Mild/moderate: Abdominal pain Arthritis Anxthmia Bronchitis Cystitis Headache Neuralgia |
| Muller     | Open-label; uncontrolled observational | 500 patients diagnosed with depression comorbid with anxiety | (1) 500 mg valerian extract and 600 mg/day St John’s Wort; (2) 1,000 mg valerian extract and 600 mg/day St John’s Wort | N/A     | 6 weeks            | Significant reduction in anxiety disorder symptoms (HAMA) in both treatment groups. Greater dosage results in greater improvements. | +                      | Allergy Bad dreams Sleep disorders Dysphoria |
| Kobak      | Randomized; Double-blind; Parallel Group | 40 subjects with GAD | St John’s Wort; flexible dose (600-1800 mg/day), mean dose at week 12 was 1676 mg/day | Placebo | 12 weeks            | No significant difference to placebo (LSAS) | -                      | Similar to placebo. Mild/moderate: Gastrointestinal upset Dizziness Insomnia Fatigue |
| Kobak      | Randomized; Double-blind; Parallel Group | 60 outpatients with primary diagnosis of OCD | St John’s wort LI 160; flexible dose (600-1800 mg/day), mean dose at week 12 was 1663 mg/day | Placebo | 12 weeks            | No significant difference to placebo (Y-BOCS) | -                      | Similar to placebo. Mild/moderate: Headache Gastrointestinal symptoms Fatigue Agitation Sleep disturbance |
| Sarris     | Randomized; Double-blind; Crossover | 28 adults with MDD and co-occurring anxiety | Hypericum perforatum (1 × 1.8 g tablet, three times/day); Kava rhizome aqueous extract (1 × 2.66 g tablet, 3 times/day) | Placebo | 4 weeks            | Combination treatment had no significant effects on anxiety (BDI-II). | -                      | No serious adverse events. Mild gastrointestinal upset. No liver toxicity |

DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale; OCD: obsessive-compulsive disorder; GAD: generalized anxiety disorder; SJW: St John’s wort; SCL-90-R-ANX: Self-Report Symptom Inventory-90 Items revised, subscore somatic anxiety; HAMA: Hamilton Anxiety Scale; ICD-10: International Classification of Diseases; LSAS: Liebowitz Social Anxiety Scale; HAMA-SOM: Hamilton Anxiety Scale, subscore somatic anxiety; CGI: Clinical Global Impressions; HAMA-PSY: Hamilton Anxiety Scale, subscore psychic anxiety; HAMA-T: Hamilton Anxiety Scale, total score; HDS: Hamilton Depression Scale; SCL-90-R: Self-Report Symptom Inventory-90 Items revised; PGI-I: Patient Global Impressions of Improvement; CGI-I: Clinical Global Impressions of Improvement; CGI-S: Clinical Global Impressions of Severity.

1. Clinician observation [case 1], SCL-90-R [case 2]; self-assessment, HAMA [case 3].
2. ICD-10: F45.0.
3. F45.1.
4. F45.3.
5. Euvegal Balance tablet; drug-extract-ratio 3-6:1.
6. Neurontin tablet; drug-extract-ratio 2.5-5:1.
7. Euvegal Balance tablet.
8. Drug/extract ratio of 3-6:1.
9. Except agitation which was higher with SJW.
10. Standardized to 990 μg of hypericin, and 1500 μg of flavone glycosides.
11. Standardized to 50 mg of kavalactones.
Results and discussion

Flow of included studies

Electronic searches found 106 papers that were potentially relevant to the present systematic review. Of these, 24 met the inclusion/exclusion criteria (see Figure 1 for a flow diagram). Of the 82 that did not meet the criteria, 21 were excluded from the main review because they were not original research (e.g. reviews or meta-analyses) or were case studies, 14 did not investigate the supplement as a treatment (e.g. safety analysis, pharmacological evaluations, study of nutritional deficiencies), 32 did not use human subjects, and 15 were published in a language other than English. Some of the excluded papers listed as reviews are cited in the background and discussion sections of this manuscript. Papers that were mainly discussions of philosophical and ethical issues were not reviewed at all.

Study characteristics

A total of 24 studies were found that met the mentioned requirements. These studies examined the effectiveness of five monotherapies (passionflower, lysine, magnesium, kava and St John’s wort) and eight combination treatments (a herbal combination, multivitamin, L-lysine + L-arginine, magnesium + vitamin B₆, herbal

Table 5 Trials testing lysine

| Reference        | Study Design | Sample Population | Intervention | Control | Length of Treatment | Outcomes                                                                 |
|------------------|--------------|-------------------|--------------|---------|---------------------|--------------------------------------------------------------------------|
| Jezova (2005) [67] | Randomized; Double-blind; Parallel Group | 29 healthy male subjects at the upper limit of the normal range of a trait anxiety scale¹ | Mixture of L-lysine and L-arginine (3 g each/day) | Placebo | 10 days | AMino acid treatment enhanced adrenocorticotropic hormone, cortisol, adrenaline and noradrenaline levels and galvanic skin responses during stress; no effect on heart rate and blood pressure. |
| Smriga (2007) [68] | Randomized; Double-blind; Parallel Group | 108 healthy Japanese adults | Oral L-lysine (2.64 g/day) and L-arginine (2.64 g/day) | Placebo | 1 week | L-lysine/L-arginine treatment significantly reduced trait and state anxiety; also decreased basal levels of salivary cortisol and chromogranin-A in male subjects |

STAI: State Trait Anxiety Inventory.

Table 6 Trials testing magnesium

| Reference        | Study Design | Sample Population | Intervention | Control | Length of Treatment | Outcomes                                                                 |
|------------------|--------------|-------------------|--------------|---------|---------------------|--------------------------------------------------------------------------|
| Carroll (2000) [75] | Randomized; Double-blind; Parallel Group | 80 healthy males | Berocca: oral multivitamin¹ | Placebo | 28 days | Multivitamin treatment significantly reduced anxiety as measured by GHQ-28, HADS and PSS. |
| De Souza (2000) [76] | Randomized; Double-blind; Crossover (4) | 44 women with adverse premenstrual symptoms but otherwise in good health | (1) 200 mg Mg, (2) 50 mg vitamin B₆, (3) 200 mg Mg + 50 mg vitamin B₆ per day | Placebo | One menstrual cycle | 200 mg/day Mg + 50 mg/day vitamin B₆ significantly reduced anxiety-related premenstrual symptoms |
| Hanus (2004) [77] | Randomized; Double-blind; Parallel Group | 264 patients with generalized anxiety (DSM-III-R) of mild-to-moderate intensity² | Sympathyl: extracts of craeagus arayacantha and eschscholtzia californica plus magnesium | Placebo | 3 months | Significant clinical improvement in anxiety³ in favour of the combination treatment |

GHQ-28: General Health Questionnaire; HADS: Hospital Anxiety and Depression Scale; PSS: Perceived Stress Scale; DMS-III-R: Diagnostic and Statistical Manual of Mental Disorders, third edition revised; HAMA: Hamilton Anxiety Scale; HAMA-SOM: Hamilton Anxiety Scale, subscore somatic anxiety; HAMA-T: Hamilton Anxiety Scale, total score (HAMA-T)

1. Multivitamin containing vitamin B₁ (15 mg), B₂ (15 mg), niacin (50 mg), pantothenic acid (23 mg), B₆ (10 mg), biotin (150 mcg), folic acid (400 mcg), B₁₂ (10 mcg), C (500 mg), calcium (100 mg), magnesium (100 mg), zinc (10 mg).
2. Total HAMA score between 16 and 28.
3. Measured by HAMA-T and HAMA-SOM and subjective patient-rated anxiety.

Headache, muscular stiffness, insomnia, drowsiness, indifference, anxiety, palpitations, nausea (4), gastralgia, diarrhea, gastric heaviness, dysuria, colic renal pain, morning sluggishness (3), asthenia.
Overall, 2619 participants between the ages of 18 and 82 took part in these studies. Twenty-eight percent were male, 63% were female and 9% did not have their gender reported (Table 1). Ethnicity/race, although an important demographic factor, was not reported in 72% of patients. As a result, it is difficult to draw any overarching conclusions from the results because these factors can significantly affect the potential for herbs to treat anxiety illnesses.

Some cultures have a greater preference for natural medicine than modern medicine, and therefore will likely exhibit positive results towards it. Because culture, gender, and age are potential confounding variables, efforts should be made to control for them in future studies.

This review presents the available evidence for passionflower, lysine, magnesium, kava and St John’s wort, either alone or in combination. Methodological details and results of these trials are summarized in Tables 2, 3, 4, 5, 6. These tables are divided according to the treatment studied and include the reference, study design, sample population, intervention, control, outcomes, direction of evidence, and reported adverse events.

Herbal Medicines

Passionflower

Passionflower or Passiflora incarnata Linn. has a long history of use as an anxiolytic agent in folklore and has been used by people all over the world to treat anxiety [26]. More importantly, several studies involving the biochemical makeup of passionflower have been conducted [27-29]. Between the 1970s and 1990s, passionflower was listed as an official plant drug by the pharmacopoeias of America, Britain, Germany, France, Switzerland, Egypt and India; its wide use has made it an acceptable treatment for restlessness and nervousness [30].

The anxiolytic effects of passionflower are well documented in mice [30,31]. However, one of the problems with herbal supplements is that plant material contains thousands of phytochemicals, making it challenging to pinpoint the specific biochemicals responsible for the anxiolytic properties. In other words, although herbal remedies often produce positive results, identifying the active ingredients can be difficult. Therefore, users of herbal remedies may be consuming ineffective or possibly toxic substances in addition to the active, anxiolytic ingredients. To date, three human trials have documented the efficacy of passionflower as a treatment for anxiety-related disorders [32-34].

One double-blind, placebo-controlled study analyzed the difference in efficacy between oxazepam, a prescription benzodiazepine used to treat chronic anxiety symptoms, and passionflower in patients (n = 36) who met the criteria for GAD [32]. The results showed no difference between the two anxiolytics with regard to the treatment of GAD, suggesting that passionflower is as effective as benzodiazepines in eliminating anxiety symptoms. Subjects from the passionflower group also reported lower job impairment performance than those in the benzodiazepine group; however, subjects in the benzodiazepine group reported a faster onset of symptom relief.

This anxiolytic effect was also seen in two other subsets of patients: those undergoing surgery (n = 60) who were treated with passionflower monotherapy [33], and those diagnosed with adjustment disorder with anxious mood (n = 182) who were treated with passionflower in combination with crataegus oxyacantha, ballota foetida, valeriana officinalis, cola nitida and paullinia cupana [34].

Mild adverse events were reported in only one study, including dizziness, drowsiness and confusion [32]. This
preliminary evidence suggests that passionflower may have a role in the treatment of anxiety and warrants future research.

**Kava**

Kava is a drink that is prepared from the plant *Piper methysticum*. It has been consumed in many cultures because it is known to relieve anxiety, restlessness and insomnia for centuries [35,36]. Several studies in animals have also demonstrated the kava plant’s abilities as an anxiolytic agent [37,38]. The attractiveness of kava is that it is anxiolytic but not sedative or mentally impairing, which are typical side effects caused by benzodiazepines [32]. The biochemical mechanism of kava’s anxiolytic activity has been postulated to occur through enhanced ligand binding to GABA type A receptors, blockage of violated-gated sodium channels and calcium ion channels, norepinephrine and dopamine reuptake inhibition, and reversible inhibition of monoamine oxidase (MAO) B [see [39] for a review]. To note, the binding of kava extracts to several neurotransmitters such as GABA$_{A_1}$, dopamine D2 and the opiates (μ and δ), were demonstrated *in vitro* and in the rat brain [40,41].

The first randomized, placebo-controlled, double-blind study of kava for the treatment of patients who were diagnosed with anxiety disorder was conducted in 1997 [42]. The subjects (*n* = 101) were given either an extract of kava or a placebo for 25 weeks. The participants who were given the kava extract showed improvement in their primary and secondary anxiety symptoms based on the HAMA – a method of patient self-reporting – and a CGI, which was determined by physicians. Primary anxiety is described as the inability to regulate stress and anxiety since early childhood. Secondary anxiety, which develops later in life, can be caused by clinical disorders. The researchers concluded that when kava is used an anxiolytic alternative to benzodiazepines or tricyclic antidepressants, individuals typically suffer from less side effects.

These results were later supported by five other RCTs [43-47] and one uncontrolled, observational study [48]. These studies showed kava’s therapeutic potential both as a monotherapy for patients with anxiety disorder [48], GAD [43,44,49], elevated generalized anxiety [47] and those being tapered off of benzodiazepines [45], as well as in combination with calcium for perimenopausal women [46].

However, four RCTs showed that kava alone or in combination with St John’s wort is no more effective than placebo in reducing symptoms of anxiety [50-53]. Two of these studies showed no significant difference between kava treatment and placebo [51,53], while one found that placebo was actually better at reducing anxiety symptoms in patients with higher baseline anxiety scores [52]. According to the researchers, this could have been partly due to the study population. In this trial, patients were actively looking for alternative treatments for their GAD and were, therefore, highly motivated for kava treatment to produce an effect. This in turn could have influenced their response to treatment and led to an increased placebo effect. It is important to note that the sample size of this study was very small. The last negative trial [50] was classified on the basis that it failed to meet its primary endpoint – a significant reduction in anxiety based on the Zung Anxiety Scale from memory. However, an exploratory analysis of variance across the differences between treatment end and baseline, with the treatment center as a second factor, showed superiority of kava over placebo. According to the researchers, this variance between centers did not endanger the validity of their findings; however, it did reinforce the importance of standardizing ratings across participating centers in multi-center studies.

All of these trials also revealed that taking doses less than 400 mg/day does not cause serious side effects. This is important to note, especially since the U.S. Food and Drug Administration (FDA) published a consumer advisory warning in 2002 about the potential for severe liver damage from kava-containing supplements [54]. This potential, yet rare, risk of hepatitis, cirrhosis and liver failure led nations such as Canada and the United Kingdom to ban kava supplements. However, Teschke *et al.* reported in 2008, that owing to the fact that kava was considered to be well tolerated until 1998 when the first reported cause of hepatotoxicity occurred, these rare, but serious side effects may have occurred due to poor quality kava, as well as other risk factors such as overdose, prolonged therapy and co-medication [55].

Of the 435 clinical trial participants taking kava supplements in our review, some at high doses, no liver issues were reported. Therefore, the current review supports the conclusion that liver toxicity is indeed a rare side effect.

**St John’s wort**

*Hypericum perforatum*, or St John’s wort (SJW), is derived from the flowering tops of a perennial shrub. It has been used in traditional medicine for centuries to treat a wide range of disorders and is licensed in Germany to treat anxiety, depression and sleep disorders [56]. There are numerous hypotheses for its anxiolytic effects based on the binding affinity of at least 10 different extracts, including naphthodianthrones like hypericins, flavonoids, xanthones, and bioflavonoids, for adenosine, GABA$_A$, GABA$_B$ and glutamine receptors, as well as the inhibition of monoamine oxidase-A and -B activity and synaptosomal uptake of serotonin, dopamine and noradrenaline (norepinephrine) [57]. Of these active ingredients, hypericin has been studied the most,
and the amount present is generally used to standardize extracts. SJW is probably most recognized for its use in depression. A meta-analysis published in 1996, showed that SJW was more effective than placebo in treating mild to moderate clinical depression [56]. Based on the author’s recommendations, researchers began comparing the efficacy and safety profile of SJW against other routinely prescribed antidepressants. One trial conducted in Germany concluded that SJW was as effective as imipramine in treating mild to moderate depression (n = 324) [58].

Depression has been linked to anxiety, with many symptoms, panic attacks for example, overlapping between the two disorders. Little is known about the specific reasons for the link in the conditions; however, there may be as high as an 85% overlap with the diagnoses and many conventional treatment options are prescribed for both disorders. There has been little study of the effectiveness of SJW in treating anxiety disorders specifically, with only four RCTs [51,59-61] and two uncontrolled observational studies [62,63].

These published studies presented contradictory results. A small 12-week observational study (n = 13) of patients with OCD showed that SJW caused significant improvements, with results comparable to those seen in clinical trials with SSRIs [63]. However, a larger 12-week RCT (n = 60) showed no significant difference between patients treated with SJW (at doses higher than the observational study) or those treated with placebo [59]. Based on previous studies, OCD has one of the lowest placebo response rates of all of the anxiety disorders [64]. For this reason, these negative results were probably due to lack of response to SJW treatment rather than the high placebo response rates noted in the negative kava trials [59].

A second set of RCTs investigated the use of SJW combination treatments for depression with co-morbid anxiety. A combination of SJW and valerian was found to significantly reduce anxiety disorder symptoms; however, greater reductions were seen with higher doses of valerian (SJW doses remained constant between treatment groups), suggesting that valerian has more of an effect on symptoms [62]. A combination of SJW and kava was shown to have no significant effects on anxiety [51].

Finally, a RCT of 149 patients with depression with co-morbid anxiety, OCD and somatization disorder demonstrated that six weeks of treatment with SJW significantly reduced anxiety [61]. However, a RCT of 40 patients diagnosed with generalized social anxiety disorder found that SJW was no more effective than placebo in reducing anxiety symptoms [60]. In the discussion of this study, the researchers stated that a negative trial was conducted but speculated that minimum severity levels may be necessary for SJW to be effective in this patient population [60].

More research needs to be done using SJW in all the indications presented in this review in order to determine its effectiveness. However, the results point to a potential anxiolytic agent with a side effect profile similar to placebo. All of the side effects reported in the reviewed trials were mild to moderate and were most often cases of gastrointestinal upset, dizziness, sleep disturbances, and headaches.

**Nutritional Supplements**

**Lysine**

It has long been postulated that the dysregulation of neurotransmitters may be a cause for anxiety. These neurotransmitters include GABA, serotonin, dopamine and norepinephrine [4-6]. Amino acids such as L-tyrosine and L-tryptophan are known precursors for specific neurotransmitters. Recent studies in animals have identified two amino acids, L-lysine and L-arginine [65,66], which may influence neurotransmitters involved in stress and anxiety. L-lysine has been shown to act as a partial serotonin receptor 4 (5-HT₄) antagonist, decreasing the brain-gut response to stress as well as decreasing blood cortisol levels [65]. Based on the results from animal studies, two placebo-controlled studies were conducted to analyze the effects of L-lysine-containing supplements in humans [67,68].

The first of these clinical trials was conducted in healthy male volunteers who were suffering from high-trait anxiety based on a STAI questionnaire [67]. Results from this study showed that L-lysine and L-arginine combination supplements improved participants’ ability to handle induced stress through an increase in cortisol, while placebo had no reported improvement of anxiety symptoms. In the discussion, the researchers attributed the increase in cortisol to a previous stress hormone regulation deficiency. A previous report indicated that during moments of induced stress, an increase in cortisol levels, which is the typical reaction in healthy persons, does not increase in people with high-trait anxiety [69]. This dysregulation of cortisol may lead to augmented feelings of anxiousness when stress is induced.

The second RCT recruited 108 healthy Japanese individuals [68]. After one week of treatment with an oral L-lysine and L-arginine supplement, basal levels of salivary cortisol decreased in male subjects (n = 54) but not in females, presumably because these participants were not selected based on high-trait anxiety. Supplementation also resulted in significant reductions in state anxiety (a temporary condition characterized by apprehension, tension and fear about a specific
situation or activity) and trait anxiety (a pre-set level of anxiety or a tendency to be anxious) in both males and females.

For the two available RCTs, it seems that the L-lysine + L-arginine combination effectively reduces anxiety scores with no reported side effects. Amino acid supplements may also help in balancing cortisol levels triggered by stress in both healthy individuals and those with high trait anxiety. However, more research needs to be conducted on both lysine combinations and monotherapy to confirm these results.

**Magnesium**

Magnesium is a positively charged ion, a cation, that is involved in many important molecular functions in the body and has been linked to anxiety-related disorders [70-74]. To date, three human trials have been conducted that test the anti-anxiety effects of increased magnesium intake in combination therapies [75-77], and all showed a positive direction of evidence.

In the first study, 28-day treatments with a multivitamin that contained large amounts of magnesium, zinc and calcium dramatically decreased psychological distress (according to the GHQ-28) compared to placebo, which worsened symptoms [75]. Results from the HADS also showed a decrease in anxiety for the treatment group. The effects became more pronounced as the multivitamin treatment progressed but could not be linked solely to magnesium supplementation.

A second study published in 2000 looked at the effects of magnesium and vitamin B6 supplementation on premenstrual-related anxiety [76]. The women were given 1) magnesium, 2) B6, 3) magnesium + B6, and 4) a placebo over four menstrual cycles, respectively. The average magnesium intake for this study was approximately 300 mg daily. The women were asked to keep a log of their symptoms and categorize them into six groups: anxiety, craving, depression, hydration, other, and total. The results showed that the combination of magnesium and B6 created a synergistic affect that provided women with the greatest relief from premenstrual anxiety. However, magnesium monotherapy was shown to provide results similar to placebo.

The third clinical study was conducted in 2004 and investigated the effects of three compounds in combination, including magnesium, versus placebo in patients diagnosed with GAD (n = 264) [77]. The researchers found that both the magnesium-containing supplement and the placebo drastically decreased anxiety systems based on HAMA, a personal assessment, and a physician’s evaluation, hinting at a potential placebo effect for this treatment. Also, due to the fact that one of the herbal extracts contained in the preparation is closely related to the opium poppy, these effects may not have been due to the action of the magnesium.

Although the exact mechanism has yet to be determined, it appears magnesium supplementation is effective at treating anxiety and anxiety-related disorders when used in combination with other vitamins, minerals and herbal extracts. However, more research of magnesium monotherapy and its pharmacology is needed to determine whether magnesium itself possesses anxiolytic characteristics. Overall, available literature shows that magnesium-containing supplements are generally well-tolerated with very few reported side effects.

**Conclusions**

Anxiety disorders are one of many common psychological ailments. Natural remedies have been used for centuries in many cultures to alleviate anxiety and its symptoms with surprising effectiveness. In Western cultures, however, research that proves the usefulness of medicinal herbs and natural substances has only begun to gain momentum over the past few decades. In addition, the absence of proper guidelines governing the production and use of vitamins, minerals, amino acids and herbs for medicinal purposes is also causing the clinical prescription of these natural treatments to lag behind in the United States.

Of the RCTs reviewed in this report, 71% (15 out of 21) showed a positive direction of evidence, and any reported side effects were mild to moderate. Based on this data, it appears that nutritional and herbal supplements are effective methods for treating anxiety and anxiety-related conditions without the risk of serious side effects. However, the effectiveness of each of the reviewed combinations and monotherapies has not been substantiated to the same degree.

Passionflower has been studied in three different RCTs, twice as a monotherapy and once as part of an herbal combination. All three of these studies showed a positive benefit for treatment with passionflower, providing good evidence of its effectiveness as an anxiolytic agent. However, since each of these studies was conducted in a different patient type, more research is needed to prove its efficacy in each indication.

Kava is the most researched supplement in this review with 11 different studies (10 RCTs and one observational). Of the RCTs of kava monotherapy, 63% (5/8) showed treatment significantly reduced anxiety symptoms in a variety of patient types. This provides good evidence for the use of kava in patients with GAD, non-psychotic anxiety and other anxiety-related disorders.

The evidence for St John’s wort was mixed, with 50% (3/6) of the studies having positive results. However, the fact that only 1 out of the 4 RCTs had a positive direction of evidence and that the active treatment in this trial was a combination of SJW and valerian suggests that SJW monotherapy should not be recommended to
patients suffering from anxiety disorders or other anxiety-related conditions.

For all three of the reviewed herbal supplements, more research needs to be done to establish the most effective dosage and to determine whether this varies between different types of anxiety or anxiety-related disorders. Furthermore, as 3 of the 4 herbal combinations showed positive results, future research should focus on determining whether herbal combinations are similarly or more effective than monotherapy as well as refining the type of herbs and dosages contained in combination supplements.

Combination nutritional supplements containing lysine or magnesium also appear to hold promise as treatments for anxiety symptoms and disorders. Both RCTs of L-lysine and L-arginine combinations demonstrated positive results, providing good but limited evidence of its usefulness as a treatment for anxiety.

The evidence for magnesium is mixed. Even though all three RCTs of magnesium-containing supplements had positive results, magnesium monotherapy was shown to be no different than placebo [76], raising the question of whether magnesium provides any anxiolytic benefits in combination or whether the results were based on the actions of the other nutrients/herbal extracts. However, this study was conducted in women with premenstrual anxiety rather than an anxiety disorder. Future research should focus on elucidating magnesium’s mode of action in order to determine if it has anxiolytic properties and provides any synergistic effects when combined with other natural anxiolytic agents.

Herbal medicines hold an important place in the history of medicine, as most of our current remedies, and the majority of those to be discovered in the future, will contain phytochemicals derived from plants. While locating the active ingredients in herbal substances is pivotal to being able to produce effective supplements, understanding the quantity needed and potency of different ways of extracting and preparing the phytochemicals is vital to creating a standard measure of their effectiveness. In addition, the dangers of overconsumption and interactions with prescription medications and over-the-counter medications need to be further analyzed. This understanding of the standards for effective preparation further minimizes the chance of side effects from herbal medicines and helps to create an undisputable body of evidence for their effectiveness.

Additional material

List of abbreviations

AMS: Adjective Mood Scale; ASI: Anxiety Sensitivity Index; BAI: Beck Anxiety Inventory; BDII: Beck Depression Inventory-II; BF-S: Belinlichkeitsskala [subjective well-being score]; CAM: complementary and alternative medicine (CAM); CGI: Clinical Global Impressions; CBT: cognitive behavioural therapy; CGI-I: Clinical Global Impressions of Improvement; CGI-S: Clinical Global Impressions of Severity; DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, third edition revised; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; EAA: Efferlang Anxiety, Tension and Aggression Scale; FDA: U.S. Food and Drug Administration; GABA: gamma-aminobutyric acid; GAD: generalized anxiety disorder; GHI-Q-28: General Health Questionnaire; HADS: Hospital Anxiety and Depression Scale; HAMA: Hamilton Anxiety Scale; HAMA-PSY: Hamilton Anxiety Scale, subscore psychic anxiety; HAMA-SOM: Hamilton Anxiety Scale, subscore somatic anxiety; HAMA-T: Hamilton Anxiety Scale, total score; HCl: hydrochloric acid; HDS: Hamilton Depression Scale; ICD-10: International Classification of Diseases, kl: kavalactones (kl); LSAS: Liebowitz Social Anxiety Scale; MAO: monoamine oxidase; MADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; NRS: numerical rating scale; OCD: obsessive-compulsive disorder; PGI-I: Patient Global Impressions of Improvement; PSS: Perceived Stress Scale; QUOROM: Quality of Reporting of Meta-analyses; RCT: randomized controlled trial; SARA: Self-Assessment of Resilience and Anxiety; SCL-90-R: Self-Report Symptom Inventory-90 Items revised; SCL-90-R-ANX: Self-Report Symptom Inventory-90 Items revised, subscore somatic anxiety; SW: St John’s wort; SSRI: Serotonin selective reuptake inhibitor; STAI: State Trait Anxiety Inventory; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SEL and KFV participated in the preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We wish to thank GNIF research consultant Magdalena Hofer, research associate Violeta Osegueda, and research assistant Nirlai J. Shah for their editing support and suggestions.

Received: 14 April 2010 Accepted: 7 October 2010

Published: 7 October 2010

References

1. Kessler RC, Chu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
2. Diagnostic and Statistical Manual of Mental Disorders Washington D.C.: American Psychiatric Association, 4 2000.
3. Vogelzangs N, Seldenerjik A, Beekman AT, van Hout HP, de Jonge P, Penninx BW. Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord 2009, 14:866-875.
4. Christmas D, Hood S, Nudd D. Potential novel anxiolytic drugs. Curr Pharm Des 2008, 14:3534-3546.
5. D’Hulst C, Atack JR, Koyy IF. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov Today 2009, 14:866-875.
6. Furmark T. Neurobiological aspects of social anxiety disorder. Br J Psychiatry Relat Sci 2009, 46:5-12.
7. Ballon D: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001, 62:46-50.
8. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry 2009, 70:25-31.
9. Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001, 62:46-50.
10. Davidson JR: First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry 2009, 70:25-31.
compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005, 20:299-304.
60. Kobak K, Taylor L, Warnier G, Futterer R: St. John’s wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005, 25:51-58.
61. Volz HP, Muck H, Kasper S, Moller HJ: St John’s wort extract (LJ 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002, 164:294-300.
62. Muller D, Phil T, von den Driesch V: Treating depression comorbid with anxiety—results of an open, practice-oriented study with St. John’s wort WS 5572 and valerian extract in high doses. Phytomedicine 2003, 10:25-30.
63. Taylor L, Kobak K: An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000, 61:575-578.
64. Huppert JD, Schultz LT, Foa EB, Barkow DH, Davidson JR, Gorman JM: Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry 2004, 161:1485-1487.
65. Smriga M, Torii K: L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc Natl Acad Sci USA 2003, 100:15370-15375.
66. Smriga M, Smriga M, Nakagawa K, Toride Y: A diet fortified with L-lysine and L-arginine reduces plasma cortisol and blocks anxiogenic response to transportation in pigs. Nutr Neurosci 2003, 6:288-289.
67. Jezova D, Makatsori A, Smriga M, Morranya Y, Duncko R: Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxiety. Nutr Neurosci 2005, 8:155-160.
68. Smriga M, Ando T, Akutsu M, Furukiya Y, Miwa K, Morinaga Y: Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomed Res 2007, 28:85-90.
69. Jezova D, Makatsori A, Duncko R, Moncek F, Jakubek M: High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1331-1336.
70. Abraham GE: Nutritional factors in the etiology of the premenstrual tension syndromes. J Reprod Med 1983, 28:446-464.
71. Durflach J, Pages N, Bac P, Bara M, Guet-Bara A: Importance of magnesium depletion with hypofunction of the biological clock in the pathophysiology of headaches with photophobia, sudden infant death and some clinical forms of multiple sclerosis. Magnes Res 2004, 17:314-326.
72. Fromm L, Heath DL, Vink R, Nimmo AJ: Magnesium attenuates post-traumatic depression/anxiety following diffuse traumatic brain injury in rats. J Am Coll Nutr 2004, 23:5295-5315.
73. German-Fattal M, Lecerf F, Sabbagh F, Maurois P, Smriga M, Torii K: Neuroprotective gene profile in the brain of magnesium-deficient mice. Biomed Pharmacother 2008, 62:364-372.
74. Poleszak E, Szewczyk B, Kedzierska E, Wlaz P, Pilc A, Nowak G: Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav 2004, 78:7-12.
75. Carroll D, Ring C, Suter M, Willemsen G: The effects of an oral multivitamin combination with calcium, magnesium, and zinc on psychological well-being in healthy young male volunteers: a double-blind placebo-controlled trial. Psychopharmacology (Berl) 2000, 150:220-225.
76. De Souza MC, Walker AF, Robinson PA, Bolland K: A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med 2000, 9:131-139.
77. Hanus M, Lafon J, Mathieu M: Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Can J Cardiol Res Opin 2004, 20:63-71.